RB1 and breast cancer: Recent clinical data from genetic analysis of ER+ BC patients given CDK4/6 inhibitors revealed multiple genetic alterations, including biallelic inactivation of Rb1, as potential biomarkers of CDK4/6 inhibitor resistance [98].